和铂医药（上海）有限公司 Harbour BioMed
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer 2024-11-15 09:55
Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease 2024-11-08 17:45
Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors 2024-10-10 11:04
Nona Biosciences Enters Strategic Collaboration with OverT Bio to Advance Next-Generation Cell Therapies for Solid Tumors 2024-10-09 20:00
Nona Biosciences Enters Strategic Collaboration with Alkyon Therapeutics for Next-Generation Immunotherapeutics Discovery 2024-09-24 20:00
Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 2024-09-14 16:06
Nona Biosciences Enters into Collaboration Agreement with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies 2024-09-13 09:27
Harbour BioMed Announces 2024 Interim Results 2024-08-28 17:44
Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 2024-07-26 10:16
Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results 2024-07-19 07:15
Nona Biosciences Enters into Collaboration Agreement with Alaya.bio to Advance CAR-T Cell Therapy 2024-07-15 10:12
Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis 2024-06-27 07:08
Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies 2024-05-23 07:23
Harbour BioMed Reports Full Year 2023 Financial Results 2024-03-28 22:10
Nona Biosciences Enters into Collaboration Agreement with Boostimmune in Antibody-Drug Conjugate Development 2024-02-27 09:23
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S. 2024-01-24 12:40
Harbour BioMed Announces Positive Profit Alert 2024-01-19 12:52
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC) 2023-12-15 07:30
Nona Biosciences Announces Collaboration with Evive Biotech to Accelerate Antibody Discovery 2023-12-11 09:00
Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics 2023-12-04 13:19
1 2 3 4 5